Are radiologists ready to evaluate true response to immunotherapy?

Insights into Imaging

Izzet Dogan¹  Sezai Vatansever¹  Sukru Mehmet Erturk²  Inci Kizildag Yirgin³ 

[1] Department of Medical Oncology, Oncology Institute, Istanbul University, 34390, Istanbul, Capa, Turkey;Department of Radiology, Istanbul Medical Faculty, Istanbul University, 34390, Istanbul, Capa, Turkey;Department of Radiology, Oncology Institute, Istanbul University, 34390, Istanbul, Capa, Turkey;

关键词: Immunotherapy;    Tumor response;    irRC;    irRECIST;    iRECIST;   

DOI  :  10.1186/s13244-021-00968-w

来源: Springer

【 摘 要 】

BackgroundStandardized response criteria for evaluating patients radiological imaging have an essential role in oncological management. Immunotherapy, using immune checkpoint inhibitors (ICIs), including drugs targeting cytotoxic T-lymphocyte-associated antigen 4 and programmed cell death protein 1 or its ligand, promise a new role that has demonstrated improvement management in cancers resistant to chemotherapy. This article reviews the literature to understand the most useful response evaluation criteria for optimal patient management under immunotherapy treatment. Areas that warrant further research are described.ConclusionIn conclusion, ICIs have become more widely accepted and used by medical oncologists. Radiologists face challenges in assessing tumor response and becoming more involved in the management of treatment. The latest published immune-RECIST criteria can be used in response assessment, but further prospective evaluation is needed with registration clinical trials to be definitively validated.

【 授权许可】

CC BY